LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Monocyte Distribution Width Predicts Sepsis in Critically Ill Patients

By LabMedica International staff writers
Posted on 06 Dec 2021
Print article
Image: The UniCel DxH 800 Coulter Cellular Analysis System (Photo courtesy of Beckman Coulter)
Image: The UniCel DxH 800 Coulter Cellular Analysis System (Photo courtesy of Beckman Coulter)
Sepsis has been reported as a major cause of increased morbidity, length of stay and mortality among patients hospitalized in Intensive Care Units (ICUs) for any cause. The survival of patients developing sepsis in the ICU is strictly related to an early diagnosis, as well as a prompt start of appropriate medical interventions.

Among biomarkers of sepsis, procalcitonin (PCT) is acknowledged as the single best parameter for patients at the ICU. However, even with serial PCT measurements, the level of sensitivity and specificity achieved for the prediction of sepsis was at best equal to 75%. Recent findings suggested using Monocyte Distribution Width (MDW), a relatively simple proxy of innate monocyte response to bacterial or fungal bloodstream invasion, as a biomarker for the early recognition of sepsis.

A multidisciplinary team of medical scientists at the University of Chieti (Chieti, Italy) and the performed an observational, prospective study to estimate the analytical performance of MDW in detecting sepsis or septic shock in patients hospitalized at the ICU of the General Hospital of Pescara (Abruzzo, Italy). Sepsis and septic shock were diagnosed according to the diagnostic criteria of the Sepsis-3 classification.

Microbiology identification and sensitivity assays were performed, using the Vitek2 system (bioMérieux, Marcy l'Etoile, France), Accelerate Pheno Test (Accelerate Diagnostics, Tucson, AZ, USA), GeneXpert (Cepheid, Sunnyvale, CA, USA), as well as disc diffusion methods and agar MIC determinations by antibiotic discs and MIC test strips (Liofilchem, Roseto degli Abruzzi, Italy). Blood cell counts including MDW were determined with the UniCel DxH800 hematologic analyzer system (Beckman Coulter, Inc., Brea, CA, USA).

The investigators reported that a total of 211 patients were observed, 129 of whom were included in the final sample due to the suspect of ensuing sepsis; of these, 74 (57%) had a confirmed diagnosis of sepsis, which was best predicted with the combination of MDW > 23.0 and PCT > 0.5 ng/mL (Positive Predictive Value, PPV: 92.6, 95% CI: 82.1–97.9). The best MDW cut-off to rule out sepsis was ≤20.0 (Negative Predictive Value, NPV: 86.4, 95% CI: 65.1–97.1). Multivariate analyses using both MDW and PCT found a significant association for MDW > 23 only (OR:17.64, 95% CI: 5.53–67.91).

The authors concluded that that MDW can be used as a novel sustainable biomarker of ensuing sepsis at the ICU, alone or in combination with PCT. Values of MDW ≤ 20 can be used to rule out sepsis (sensitivity = 95.9%, NPV = 86.4%). On the other hand, MDW > 23 can be used to rule in sepsis (PPV = 90.2%), with a slight gain when used in combination with PCT > 0.5 ng/mL (PPV = 92.6%). The study was published on November 22, 2021 in the journal BMC Emergency Medicine.

Related Links:
University of Chieti
General Hospital of Pescara
bioMérieux
Cepheid
Accelerate Diagnostics
Liofilchem
Beckman Coulter


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.